Home

Chinese

Sitemap

Contact Us

Glossary

¡¡Eradication of Cancer Cells via Regeneration

1. Killing of Cancer and Transformed Cells in vitro
2. Selective Killing of Cancer Cells Co-Cultured with Normal Cells
3. Promoting Growth of Normal Cells in vitro
4. Differential Metabolism of MEBO Regenerative Nutrients in Cancer and Normal Cells
5. Killing of Cancer Cells in Tumor Tissue in vitro
6. Suppression of Ascites Tumor Growth in Animal Tumor Models
7. Eradication of Skin Cancer in Patients
8. Eradication of Leukemia in Patients
9. Regeneration of internal organs of cancer patients
10. Ongoing Clinical Studies of End-Stage Cancer Patients

8. Eradication of Leukemia in Patients

Oral formulations of the MEBO regenerative nutrients have been used as nutritional support for end-stage cancer patients who have given up medical treatment of cancer. 

As shown in Figure 10.8.1, a patient (female, age 43) was diagnosed with acute myeloid leukemia (AML-M2a) 6 years ago and went into remission after treatment with chemotherapy.  In October 2007 her leukemia reoccurred and was resistance to treatment with chemotherapy. As shown in Figure 10.8.1a, peripheral blood and bone marrow smear tests showed that cells in the granulocyte series accounted for 35.5% with the myeloblast count in her bone marrow increased to 25.5% with varied sizes and irregular morphology.  

Starting January 2008 she gave up medical cancer treatment and started taking the MEBO regenerative nutrients as nutritional support.  One and a half months later, peripheral blood and bone marrow smear tests showed that cells in the granulocyte series accounted for 44% with no myeloblast detected, and cells in all phases showed generally normal ratios and morphology; red blood cell series accounted for 26%; and cells in all phases showed generally normal ratios and morphology (Figure 10.8.1b).  After 3 months on the MEBO regenerative nutrients, her overall condition improved significantly with healthier complexion, better quality sleep, and gained about 5 Kg of weight (Figure 10.8.1c).

These results demonstrate that systemic uptake of the MEBO regenerative nutrients can cause complete remission of relapsed AML and full restoration of normal hematological cell counts, ratios and morphology.   Such results are extremely encouraging and shed new light into innovative treatment of late-stage leukemia without intervention using chemotherapy or hematological/stem cell transplantation.  The fact that the patient¡¯s hematological cell counts, ratios and morphology have been fully restored suggests that the MEBO regenerative nutrients may act on the source of all hematological cells: the hematopoietic stem cells, by promoting proliferation and differentiation of the stem cells that follow the correct, normal lineages while inducing death of leukemia cells, thereby regenerating the hematological system and eradicating cancer.  Further human studies led by MEBO are under way in larger patient populations in China. 

 

 
   
¡¡ACHIEVEMENTS
Introduction
Core Science & Technology of MEBO
Exploration of Fundamental Mechanisms of Adult Human Body Regeneration
Eradication of Cancer Cells via Regeneration
 









About us | Contact us | Link | Version | Sitemap | Glossary
Copyright© 2009 mebo.Com .All Rights Reserved